AGENUS INC (AGEN)
Data as of , from SEC Form 4 filings.
See up to 3 months of AGEN. The 7-day demo opens the 1M and 3M ranges and puts AGEN on your watchlist.
Start 7-day demoLatest AGEN insider trades
About AGENUS INC (AGEN)
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
- LEXINGTON, MA
- 81
- 2000
- Nasdaq
AGEN Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 3 | 13,122 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
AGEN insider transactions (Form 4)
3586 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 1 of 3.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Grant or award | Deferred Stock Units | 1,179 | - footnote F3 | - | ||
| ||||||
| Grant or award | Common Stock | 4,443 | $6.89 footnote F2 | $31K | ||
| ||||||
| Marco Tullio Marcucci - Director | Grant or award | Stock Option | 7,500 | $0.00 | - | |
| Grant or award | Stock Option | 1,971,500 | $0.00 | - | ||
| Grant or award | Stock Option | 50,000 | $0.00 | - | ||
| Brian Corvese - Director | Grant or award | Stock Option | 100,000 | $0.00 | - | |
| Grant or award | Stock Option | 50,000 | $0.00 | - | ||
| Steven J. O'Day - Officer | Grant or award | Stock Option | 100,000 | $0.00 | - | |
| Susan B. Hirsch - Director | Grant or award | Stock Option | 50,000 | $0.00 | - | |
| Grant or award | Stock Option | 200,000 | $0.00 | - | ||
| Grant or award | Common Stock | 4,852 | $3.35 footnote F2 | $16K | ||
| ||||||
| Grant or award | Common Stock | 8,547 | $3.58 footnote F2 | $31K | ||
| ||||||
| Grant or award | Deferred Stock Units | 2,268 | - footnote F3 | - | ||
| ||||||
| Grant or award | Common Stock | 5,364 | $3.03 footnote F2 | $16K | ||
| ||||||
| Grant or award | Common Stock | 4,925 | $3.30 footnote F2 | $16K | ||
| ||||||
| Grant or award | Common Stock | 4,644 | $3.50 footnote F2 | $16K | ||
| ||||||
| Grant or award | Common Stock | 4,540 | $3.58 footnote F2 | $16K | ||
| ||||||
| Grant or award | Common Stock | 4,233 | $3.84 footnote F2 | $16K | ||
| ||||||
| Susan B. Hirsch | Grant or award | Stock Option | 105,000 | $0.00 | - | |
| Grant or award | Stock Option | 300,000 | $0.00 | - | ||
| Grant or award | Stock Option | 5,000 | $0.00 | - | ||
| Steven J. O'Day - Officer | Grant or award | Stock Option | 70,000 | $0.00 | - | |
| Steven J. O'Day - Officer | Grant or award | Stock Option | 95,333 | $0.00 | - | |
| Grant or award | Stock Option | 122,500 | $0.00 | - | ||
| Grant or award | Stock Option | 105,000 | $0.00 | - | ||
| Austin Charette - Officer | Grant or award | Stock Option | 5,000 | $0.00 | - | |
| Austin Charette - Officer | Grant or award | Stock Option | 17,619 | $0.00 | - | |
| Grant or award | Stock Option | 1,000,000 | $0.00 | - | ||
| Grant or award | Stock Option | 27,750 | $0.00 | - | ||
| Grant or award | Stock Option | 137,550 | $0.00 | - | ||
| Brian Corvese | Grant or award | Stock Option | 210,000 | $0.00 | - | |
| Grant or award | Common Stock | 3,403 | $4.79 footnote F2 | $16K | ||
| ||||||
| Grant or award | Common Stock | 9,228 | $3.32 footnote F2 | $31K | ||
| ||||||
| Grant or award | Common Stock | 4,629 | $3.33 footnote F2 | $15K | ||
| ||||||
| Grant or award | Deferred Stock Units | 2,448 | - footnote F3 | - | ||
| ||||||
AGEN insider trading FAQ
What is the latest insider trade for AGEN?
AGENUS INC (AGEN) had 3 insider filings in the last 90 days, with the most recent on 2 October 2026. The full record for AGEN runs to 86 Form 4 filings, the earliest from 3 October 2024. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying AGEN stock?
No insider purchases of AGEN were filed in the last 90 days.
How many insiders are selling AGEN stock?
No insider sales of AGEN were filed in the last 90 days.
Where can I see AGEN SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects AGEN Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Timothy Wright view on EDGAR
- - Thomas L. Harrison view on EDGAR
- - Marco Tullio Marcucci view on EDGAR
- - Garo H. Armen view on EDGAR
- - Thomas L. Harrison view on EDGAR
- - Brian Corvese view on EDGAR
- - Timothy Wright view on EDGAR
- - Steven J. O'Day view on EDGAR
- - Susan B. Hirsch view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where AGEN's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow AGEN with a 7-day demo
- AGEN on your watchlist
- Every AGEN Form 4 filing on record
- Up to 3 months of AGEN price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive